Non–Small Cell Lung Cancer Coverage from Every Angle

Nasser K. Altorki, MD: Expert Perspective on the IMpower010 Study of Atezolizumab for NSCLC

Posted: Wednesday, October 13, 2021

Nasser K. Altorki, MD, of Weill Medical College of Cornell University and NewYork-Presbyterian Hospital, discusses phase III findings on the benefits of atezolizumab in patients with stage II–IIIA non–small cell lung cancer, and what the data suggest for treating patients with this agent in the adjuvant setting.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.